Effects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using Prevenar

Dept of Rheumatology, Lund University Hospital, Lund, Sweden0 个研究点目标入组 500 人开始时间: 2007年12月20日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•All patients with chronic arthritis treated with biologic agents ( such as TNF-blockers, IL-1 blocker or those receiving anti-CD20 treatment) at Dept of Rheumatology in Lund and followed up with structured clinical protocol are eligible for this study. Thus the following groups of patients are planned to be studied:
•RA patients on methotrexate and/or other DMARDs
•RA patients on anti-TNF drugs as monotherapy
•RA patients on anti-TNF +MTX and/or other DMARDs
•Spondylarthropathy patients on anti-TNF drugs as monotherapy
•Spondylarthropathy patients on anti-TNF drugs +MTX
•Spondylarthropathy patients on NSAIDs
•(There is a possibility to stratify for steroid use).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•age<18 years, pregnancy, allergi against the active substance in the vaccine, treatment with bilogical agens for conditions other than rheumatoid arthritis (RA) or spondylarthrophaties, ongoing infection

发起方

Dept of Rheumatology, Lund University Hospital, Lund, Sweden